Synapse - Jaap Jan Boelens

Results (4)

Phase II study of pharmacokinetic model-based ATG dosing to improve survival through enhanced immune reconstitution in patients undergoing ex vivo CD34-selected allogeneic HCT (PRAISE-IR)

Meeting Abstract

Scordo, M.; Perales, M. A.; Mauguen, A.; Lin, A.; Kunvarjee, B.; Bieler, J.; Nguyen, L. K.; Paes Pena, M.; Cho, C.; Gyurkocza, B.; more...
Bone Marrow Transplantation (2024)

Fulltext@MSK | Save

Association between busulfan exposure and survival in patients undergoing a CD34(+) selected stem cell transplantation

Journal Article

Tamari, R.; Scordo, M.; Kunvarjee, B. M.; Proli, A.; Lin, A.; Flynn, J.; Cho, C.; Devlin, S.; Klein, E.; Boulad, F.; more...
Blood Advances (2023)

Fulltext@MSK | Save

Evaluation of melphalan exposure in lymphoma patients undergoing BEAM and autologous hematopoietic cell transplantation

Journal Article

Dahi, P. B.; Lin, A.; Scordo, M.; Flynn, J. R.; Devlin, S. M.; Ruiz, J. D.; DeRespiris, L.; Carlow, D.; Cho, C.; Lahoud, O. B.; more...
Transplantation and Cellular Therapy (2022)

Fulltext@MSK | Save

Population pharmacokinetics of melphalan in a large cohort of autologous and allogeneic hematopoietic cell transplantation recipients: Towards individualized dosing regimens

Journal Article

Shah, G. L.; Boelens, J. J.; Carlow, D.; Lin, A.; Schofield, R.; Cruz Sitner, N.; Alperovich, A.; Ruiz, J.; Proli, A.; Dahi, P.; more...
Clinical Pharmacokinetics (2022)

Fulltext@MSK | Save